Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 29, 2012
Dec. 31, 2011
Jan. 01, 2011
Cash flows from operating activities:      
Net income $ 37,398 $ 37,677 $ 21,400
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 7,186 6,721 6,873
(Gain) loss on disposal of assets 193 (32) (43)
Gain on Investment in HCT   (1,244)  
Stock-based compensation expense 2,333 1,752 1,149
Deferred director and phantom stock unit expense (income) 20 (22) 557
Stock compensation income tax benefit (88) (144) (175)
Allowance for doubtful accounts 26 1 (8)
Provision for slow moving inventory (298) (19) (159)
Provision for deferred income taxes 325 1,419 622
(Increase) decrease in, net of acquisition:      
Accounts receivable 1,903 741 (6,442)
Inventories 678 (1,593) (2,815)
Income taxes receivable (520) 1,178 506
Other current assets (650) (662) (759)
Other assets, net 240 (1,081) 750
Increase (decrease) in, net of acquisition:      
Accounts payable (742) 499 861
Accrued expenses and other liabilities 4,547 4,390 2,775
Other noncurrent liabilities (353) (37) (2)
Net cash from operating activities 52,198 49,544 25,090
Cash flows from investing activities:      
Proceeds from sale of joint venture   1,451  
Acquisition of business, net of cash acquired (1,140) (1,776)  
Capital expenditures (13,359) (10,143) (3,856)
Proceeds from dispositions of equipment 56 35 175
Purchases of marketable securities (40,495) (26,833) (14,175)
Proceeds from sale of marketable securities 32,912 7,517 10,230
Net cash used in investing activities (22,026) (29,749) (7,626)
Cash flows from financing activities:      
Repayment of debt (169) (100)  
Proceeds from exercise of stock options   61 44
Stock compensation income tax benefit 88 144 175
Proceeds from stock issued 700 574 423
Dividends to shareholders (40,900) (9,596) (14,635)
Change in restricted cash (272) 84  
Net cash used in financing activities (40,553) (8,833) (13,993)
Effect of exchange rate changes on cash and cash equivalents 2,025 (1,334) (579)
Net increase (decrease) in cash and cash equivalents (8,356) 9,628 2,892
Cash and cash equivalents, beginning of period 42,834 33,206 30,314
Cash and cash equivalents, end of period 34,478 42,834 33,206
Cash paid:      
Income taxes 18,739 17,456 9,290
Supplemental disclosure of noncash transactions:      
Common stock issued for shared distribution through accrued expenses and other liabilities 4,407 2,412  
Common stock issued for deferred director's compensation through other noncurrent liabilities 930    
Unrealized gain (loss) on available for sale securities $ 326 $ (549) $ (59)